Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine

AIDS

Volumn 13, Issue 11, 1999, Pages

  Mobley, Jane E ^a,d   Pollard, Richard B ^a,b   Schrader, Shannon ^a,b,c   Adler, Myra H ^a,b,c,d   Kelleher, Thomas ^a,b,c,d   McLaren, Colin ^a,b,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c Montrose Clinic   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antiretroviral therapy; Didanosine; HIV 1; Reverse transcriptase inhibitor; Stavudine

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CD4 ANTIGEN; CREATININE; DIDANOSINE; STAVUDINE; TRIACYLGLYCEROL LIPASE; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CARDIOMYOPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPEPSIA; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION; INSOMNIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NAUSEA; NEUROPATHY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PANCREATITIS; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIALOADENITIS; THROMBOCYTOPENIA; UNITED STATES; VIRUS LOAD; VOMITING;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; STAVUDINE; TREATMENT OUTCOME;

EID: 0032839925     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199907300-00003     Document Type: Article

References (22)

1. Ahluvvalia G, Cooney DA, Hartman NR, et aJ. Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyadenosine. Drug Metabol Dispos 1993, 21:369-376.
2. Hoetelmans RMVV, Van Héeswijk RPG, Profijt M, et aJ. The pharmacokinetics of didanosine (ddl) are equivalent in once daily (QD) and twice daily (BID) regimen. 4th International Congress on Drug Therapy in HIV Infection. Glasgow, November 1998 [abstract P39).
3. Cooley TP, Kunches LM, Saunders ÇA, et al. Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyadenosine given once daily. Rev Infect Dis 1990, 12:5552-5560.
4. Reynes J, Montes B, Delmas B, Vendrell JP, Janbon F, Segondy M. Once-daily administration of didanosine with anti-retroviral zidovudine in previously untreated patients. Palhol Biol 1997,45:441-444.
5. Reynes J, Denisi R, Bicart-See A, Izopet J, Pellegrin I, Segondy M. STADI: sustained efficacy of once daily administration of didanosine in combination with stavudine. 12th World AIDS Conference. Geneva, June-July 1998 [abstract 12351).
6. Dahan V, Quinson AM, Chadapaud S, Ravaux l, Gallais H. Once daily administration of DDI in combination with D4T among naive HIV infected patients. 4th International Congress on Drug Therapy in HIV Infection. Glasgow, November 1998 [abstract P129).
7. Angarano G, Monno P, Cargnel A, et al. Comparison of once and twice daily dosing of didanosine in combination with stavudine in of HIV infected subjects. 4th International Congress on Drug Therapy in HIV Infection. Glasgow, November 1998 [abstract P80J.
8. Dona C, De Mendoza C, Soriano V, Rodrîguez-Rosado R, Gonzâlez-Lahoz J. Short-term efficacy and safety of DDI and 3TC both once daily plus indinavir BID. 4th International Congress on Drug Therapy in HIV Infection. Glasgow, November 1998 [abstract P102].
9. Flepp M, Wang ], Nigg C, et aJ. Nelfinavir, didanosine and stavudine in HIV-infected drug users enrolled in opiate substitution programs at four outpatient clinics - The Zurich Prometheus Study. 4th International Congress on Drug therapy in HIV Infection. Glasgow, November 1998 [abstract P98].
10. Raffi F, Reliquet V, Francois C, et al. Stavudine-didanosinenevirapine: a convenient highly active triple combination for first line anlirelroviral therapy. 12th World AIDS Conference. Geneva, June-July 1998 [abstract 12239).
11. Rusnak J, Berry A, Stinnette B, et al. DDI once daily vs twice daily alone and also with hydroxyurea once daily. 12th World AIDS Conference. Geneva, June-July 1998 [abstract 123521.
12. Deminie C, Bechtold C, Stock D, et al. Evaluation of d4T, ddl and BMS-186,318, in two-drug combinations against HIV replication. Third Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February 1996 [abstract 294].
13. Merrill DP, Moonis M, Chou TC, Hirsch MS. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. I Infect Dis 1996, 173:355-364.
14. Saimot AC, Landman R, Damond F, et al. Ritonavir, stavudine (d4T), didanosine (ddl) as a triple combination treatment in antiretroviral-naive patients. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 246].
15. Hengge U, Brockmeyer NH, Exner V, Beckman A, Goos M. Stavudine (d4T), didanosine (ddl), and nelfinavir combination therapy in pretreated HIV-patients: antiviral effect and safety in an ongoing study. J2th World AIDS Conference. Geneva, June-July 1998 (abstract 12226].
16. Rutschmann OT, Opravil M, Iten A, et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. AIDS 1998, 12:F71-F77.
17. Auger S, Ferre-Aubineau V, Monpeho S, Reliquet V, Billaudcl S, Raffi F. Cenotypic analysis and phenotypic susceptibility of HIV-1 isolates from patients treated with stavudine (d4T)didanosine (ddl) combination. Eleventh International Conference on Antiviral Research. San Diego, April 1998 [abstract 77).
18. Coakley E, Cillis J, Pedneault L, Dunkle L, Hammer S. Susceptibilities of HIV-1 isolates derived from patients treated with didanosine (ddl) and stavudine (d4T) in combination. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 575].
19. Pollard R, Peterson D, Hardy D, et al. Stavudine (d4T) and didanosine (ddl) combination therapy in HIV-infected subjects: antiviral effect and safety in an ongoing pilot randomized double-blinded trial. Xlsl International Conference on AIDS. Vancouver, July 1996 [abstract Th.B.293].
20. Molina JM, Chêne G, Ferchal F, et al. ALBI (ANRS 070). A randomized controlled trial to evaluate the efficacy and safety of AZT/3TC versus alternating d4T/ddl and AZT/3TC in treatment naive HIV-infected patients. 72th World AIDS Conference. Geneva, June-July 1998 (abstract 122271.
21. Ruxrungtham K, Kroon E, Ungsedhaphan C, et al. Study HIVNAT 002: the safety and efficacy of didanosine (ddl) plus or minus stavudine (d4T) in high/low dose combinations in an antiretroviral therapy naive Thai adult population with CD4 counts 150-350/mm3 and predominantly infected with HIV-1 clade E. 72th World AIDS Conference. Geneva, June-July 1998 [abstract 12241J.
22. Pell C, Slade MA, Donovan B, Bodsworth NJ. Efficacy of the combination stavudine (d4T), didanosine (ddl) and nevirapine (NVP) as initial antirctroviral therapy and following treatment with HIV-1 protease inhibitors. 72th World AIDS Conference. Geneva, June-July 1998 [abstract 12357).